This is a routine conference attendance press release with no new material data. Monitor the U.S. FDA pivotal trial enrollment completion and any subsequent data readouts for the next catalyst.
Price Chart
Executive Summary
Regentis Biomaterials reported strong surgeon interest in its GelrinC hydrogel implant at the 8th ICRS Summit in Portugal (October 8-10, 2026). The press release highlights engagement with orthopedic surgeons, CE Mark approval in Europe, expansion of Centers of Excellence, and the ongoing U.S. FDA pivotal Phase III trial which has completed over 50% enrollment. No financial data, new clinical results, or regulatory milestones were disclosed.
Key Facts
- GelrinC is CE Mark approved in Europe and is being evaluated in a U.S. FDA pivotal Phase III trial that has completed over 50% enrollment.
- Phase II study showed approximately 100% greater improvement in overall KOOS scores vs historical microfracture controls at two years.
- GelrinC is delivered in a single 10-minute procedure without cell harvesting or lab processing.
- Company is expanding its network of European Centers of Excellence for surgeon training and commercialization.
- No financial results, new clinical data, or regulatory updates were provided in this filing.
Financial Impact
No financial figures disclosed; filing is a routine business update with no quantifiable impact.
Risk Factors
- No new clinical or regulatory milestones achieved; commercial adoption in Europe remains uncertain.
- Forward-looking statements subject to risks including trial outcomes, FDA approval, and competition.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-108632 |
| Document: ea0308320-6k_regentis.htm | 0001213900-26-108632 |
| Document: 0001213900-26-108632-index-headers.html | 0001213900-26-108632 |
| Document: 0001213900-26-108632-index.html | 0001213900-26-108632 |
| Document: 0001213900-26-108632.txt | 0001213900-26-108632 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 6-K | $1.63 | awaiting T+20 | — | $1.28 (−21.23%) |
Sep 23, 2026 4w ago | EFFECT | $2.10 $1.49 | ▼ −29.05% | ▼ −29.74% | $1.28 (−39.05%) |
Jul 20, 2026 14w ago | 6-K | $2.00 $2.04 | ▲ +2.00% | ▼ −2.12% | $1.28 (−36.00%) |
Jul 15, 2026 14w ago | 6-K | $2.43 $1.94 | ▼ −20.16% | ▼ −22.51% | $1.28 (−47.33%) |
Jul 14, 2026 14w ago | EFFECT | $2.54 $1.84 | ▼ −27.56% | ▼ −30.05% | $1.28 (−49.61%) |
Jun 15, 2026 19w ago | 6-K | $9.40 $2.43 | ▲ +74.15% | ▲ +74.15% | $1.28 (+86.38%) |
Jun 9, 2026 19w ago | F-1/A | $2.41 $3.64 | ▲ +51.04% | ▲ +49.59% | $1.28 (−46.89%) |
Jun 8, 2026 20w ago | 6-K | $1.28 $3.58 | ▲ +179.69% | ▲ +178.85% | $1.28 (−0.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers